FINANCIAL INFORMATION

Short-term investments as of December 31, 2016 indicated below consisted of the following

available-for-sale debt securities:

Gross

Gross

Fair Value (Net

Amortized Cost

Gains

Losses

Unrealized

Unrealized

Carrying
Amount)

(US dollars in thousands)

U.S. Treasury securities.........................

$

280,757

$

— $

97

$

280,660

Accounts receivable

Trade accounts receivable are recorded at their invoiced amounts, net of allowances for doubtful
accounts. An allowance for doubtful accounts is recorded when the collection of the full amount is no
the Company considers
longer probable. In evaluating the collectability of receivable balances,
specific evidence including aging of the receivable,
its current
creditworthiness and current economic trends. Accounts receivable are written off after all collection
efforts have ceased. The Company regularly reviews the adequacy and appropriateness of any
allowance for doubtful accounts. No allowance for doubtful accounts was recorded as of March 31,
2018 and December 31, 2017 and 2016.

the customer’s payment history,

The Company’s accounts receivable balance totaled US$23.5 million and US$29.4 million as of
March 31, 2018 and December 31, 2017 and related entirely to trade receivables from sales of Celgene
branded products in the PRC. The Company had no accounts receivable as of December 31, 2016.

The following table sets forth an aging analysis of our accounts receivable as of the dates

indicated:

As of March 31,

As of December 31,

2018

2017

2016

(US dollars in thousands)

Within 3 months .........................................................
3 months to 6 months .................................................

Total ..........................................................................

$

$

23,485
—

23,485

$

$

18,907
10,521

29,428

$

$

—
—

—

As at the Latest Practicable Date, the accounts receivable as of December 31, 2017 and March

31, 2018 were fully settled.

Unbilled receivable

The Company’s unbilled receivable balance of US$23.9 million as of March 31, 2018 and
US$16.3 million as of December 31, 2017 related entirely to reimbursement revenue on research and
development costs of clinical trials that Celgene opted into. The Company had no unbilled receivable
as of December 31, 2016.

— 281 —

